Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2015





Global Markets Direct’s, ‘Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2015’, provides an overview of the Human papillomavirus (HPV) Associated Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Human papillomavirus (HPV) Associated Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 
Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2015
Table of Contents
Introduction 9
Global Markets Direct Report Coverage 9
Human papillomavirus (HPV) Associated Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Overview 11
Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis 12
Human papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 13
Human papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 16
Human papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Human papillomavirus (HPV) Associated Cancer - Products under Development by Companies 20
Human papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 22
Human papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 23
3SBio Inc. 23
Abivax 24
Admedus Ltd 25
Antigen Express, Inc. 26
Bionor Pharma ASA 27
Cancer Therapeutics CRC Pty Ltd 28
Etubics Corporation 29
EyeGene, Inc. 30
Formune S.L. 31
Genexine, Inc. 32
iBio, Inc. 33
Inovio Pharmaceuticals, Inc. 34
MedImmune, LLC 35
Merck & Co., Inc. 36
Novartis AG 37
Onconova Therapeutics, Inc. 38
Prima BioMed Ltd. 39
Profectus BioSciences, Inc. 40
Redbiotec AG 41
Sirnaomics, Inc. 42
Theravectys S.A. 43
Transgene SA 44
Vaccibody AS 45
Virometix AG 46
ViroStatics, srl 47
Human papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 52
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
ABX-318 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AEH-10p - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
alpelisib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Antibodies to Target E7 for HPV Associated Cancer - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Cell Therapy to Target HPV-16 E6 Protein for Papillomavirus Associated Cancers - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
durvalumab + tremelimumab - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
EDA-HPVE7 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
EG-HPV - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Gene Therapy for Papillomavirus Associated Cervical Carcinoma - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
GX-188E - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
HPV Vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
human papillomavirus (7-valent) vaccine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
human papillomavirus (9-valent) vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
human papillomavirus [Serotype 16] vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
human papillomavirus vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
human papillomavirus vaccine - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
INO-3106 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
INO-3112 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
RBT-201 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
rigosertib sodium - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SSS-08 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
STP-909 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
STP-911 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
TG-4001 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Vacc-HPV - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Vaccine for HPV Associated Cancer - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Vaccine for HPV Associated Cancers - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Vaccine for HPV Associated Cancers - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Vaccine for HPV Associated Head and Neck Cancer - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Vaccine for HPV Associated Skin Cancer - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Vaccines for HPV Associated Cervical Cancer - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
VB-1016 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Vicoryx - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Human papillomavirus (HPV) Associated Cancer - Recent Pipeline Updates 105
Human papillomavirus (HPV) Associated Cancer - Dormant Projects 115
Human papillomavirus (HPV) Associated Cancer - Product Development Milestones 116
Featured News & Press Releases 116
Dec 10, 2014: FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV 116
Mar 05, 2014: Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza 117
Nov 04, 2013: Merck's Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study 117
Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine 119
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 120
Contact Us 120
Disclaimer 121

List of Tables

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2015 11
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Development, H1 2015 19
Products under Development by Companies, H1 2015 20
Products under Development by Companies, H1 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Human papillomavirus (HPV) Associated Cancer - Pipeline by 3SBio Inc., H1 2015 23
Human papillomavirus (HPV) Associated Cancer - Pipeline by Abivax, H1 2015 24
Human papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H1 2015 25
Human papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H1 2015 26
Human papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H1 2015 27
Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2015 28
Human papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H1 2015 29
Human papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H1 2015 30
Human papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H1 2015 31
Human papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H1 2015 32
Human papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H1 2015 33
Human papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 34
Human papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H1 2015 35
Human papillomavirus (HPV) Associated Cancer - Pipeline by Merck & Co., Inc., H1 2015 36
Human papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H1 2015 37
Human papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H1 2015 38
Human papillomavirus (HPV) Associated Cancer - Pipeline by Prima BioMed Ltd., H1 2015 39
Human papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H1 2015 40
Human papillomavirus (HPV) Associated Cancer - Pipeline by Redbiotec AG, H1 2015 41
Human papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H1 2015 42
Human papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys S.A., H1 2015 43
Human papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H1 2015 44
Human papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H1 2015 45
Human papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H1 2015 46
Human papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics, srl, H1 2015 47
Assessment by Monotherapy Products, H1 2015 48
Assessment by Combination Products, H1 2015 49
Number of Products by Stage and Target, H1 2015 51
Number of Products by Stage and Mechanism of Action, H1 2015 53
Number of Products by Stage and Route of Administration, H1 2015 55
Number of Products by Stage and Molecule Type, H1 2015 57
Human papillomavirus (HPV) Associated Cancer Therapeutics - Recent Pipeline Updates, H1 2015 105
Human papillomavirus (HPV) Associated Cancer - Dormant Projects, H1 2015 115

List of Figures

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2015 11
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Products, H1 2015 19
Assessment by Monotherapy Products, H1 2015 48
Number of Products by Top 10 Targets, H1 2015 50
Number of Products by Stage and Top 10 Targets, H1 2015 50
Number of Products by Top 10 Mechanism of Actions, H1 2015 52
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 53
Number of Products by Top 10 Routes of Administration, H1 2015 54
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 55
Number of Products by Top 10 Molecule Types, H1 2015 56
Number of Products by Stage and Top 10 Molecule Types, H1 2015 56